<DOC>
	<DOCNO>NCT02359474</DOCNO>
	<brief_summary>This trial compare trabectedin alone trabectedin combination regional hyperthermia patient high-risk soft tissue sarcoma . The study design demonstrate significant benefit sarcoma-therapy add regional hyperthermia .</brief_summary>
	<brief_title>Hyper-Thermia Enhanced Anti-tumor Efficacy Trabectedin</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Age &gt; 18 year Histologically confirm STS ( primary recurrent ) , except : Ewing sarcoma , osteosarcoma , skeletal chondrosarcoma ( extraskeletal chondrosacomas include ) , GIST , dermatofibrosarcoma protuberans , malignant mesothelioma , rhabdomyosarcoma Patients failure firstline chemotherapy ( anthracyclines ifosfamide ) without RHT Progressive recurrent tumor unresectable resectable adverse functional outcome After macroscopic incomplete resection marginal resection ( tumorfree margin &lt; 1 cm ) Prior chemotherapy , include anthracyclines ifosfamide ( without RHT ) patient give medicine Oligometastasis ( â‰¤ 5 lesion ) Performance status ( ECOG ) 0,1 2 More 3 week last treatment Neutrophil count &gt; 1,5 G/l , hemoglobin &gt; 9 g/dl , platelet &gt; 100 G/l Albumin &gt; 25 g/l , total bilirubin &lt; 1 x ULN , ALT/AST &lt; 2.5 x ULN , AP &lt; 2.5 x ULN , Cockroft Gault 's calculated creatinine clearance &gt; 30 ml/min , CPK &lt; 2.5 x ULN Patients ability follow study instruction likely attend complete require visit Written inform consent subject Uncontrolled infection ( e.g . active viral hepatitis ) Unstable cardiac status Peripheral neuropathy &gt; grade 2 Known persistent abuse medication , drug alcohol Other malignancy last 5 year ( exclusion basal cell carcinoma adequately treat cervical carcinoma situ ) Prior therapy Tr know history hypersensitivity drug similar chemical structure Pregnancy breastfeeding Females childbearing potential , use willing use medically reliable method contraception entire study duration Uncontrolled CNSmetastases Medical technical impossibility hyperthermia heat major target lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>high-risk soft tissue sarcoma</keyword>
	<keyword>trabectedin</keyword>
</DOC>